Hansen reported losses of -$12.3 million, or 11¢ per share, on sales of $6.9 million during the 3 months ended June 30, paring losses by 8.6% on 106.0% sales growth compared with Q2 2013.
"Hansen Medical continued to progress through the first half of fiscal year 2014," CEO Cary Vance said in prepared remarks. "Everything I have learned to date supports my belief that the company has an innovative portfolio of intravascular robotic technology, which improves patient outcomes in cardiac arrhythmia and endovascular procedures. Since joining the company in May, I have been focused on global commercialization efforts and continuing to deliver an excellent customer experience to each of our Hansen customers, and look forward to sharing my vision for the company in the coming quarters."
Hansen also said it exchanged roughly 90% of its $1.50 Series B and $2.00 Series C warrants for Series B/C warrants for some 24.4 million shares at $1.13 apiece, HNSN’s July 29 closing price.
The warrant exercise is slated to net $23.1 million for Hansen, according to a press release. An additional offering of some 6.3 million Series D warrants at $1.13 is slated to bring in another $7.1 million, Hansen said.
HNSN shares were trading at $1.18 apiece as of about noon Eastern today, down 1.7%.